Lupus & antiphospholipid syndrome
Significant heightened methylation levels of RUNX3 gene promoter in patients with systemic lupus erythematosus
Authors' conclusion
The findings of this study emphasize the potential use of RUNX3 methylation levels in PBMCs of SLE patients as biomarkers for diagnosing the disease, predicting renal damage, and assessing disease activity.
Study context
- Population
- Individuals diagnosed with systemic lupus erythematosus (SLE) from Iran and healthy individuals
- Participants
- 80 vs 77
- Comparison
- SLE vs healthy individuals
- SLEn = 80
- Healthy individualsn = 77reference
- Outcome
- Methylation level of the RUNX3 promoter in peripheral blood mononuclear cells (PBMCs) (MethyQESD method)
Main finding
As reported in the abstract
RUNX3 promoter methylation
- RUNX3 promoter methylation significantly higher in SLE than in healthy individuals
- SLE vs Healthy individuals: P < 0.001
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| RUNX3 promoter methylation, SLE with vs without renal involvement (subgroup) | P < 0.001 |
- Diagnostic power of RUNX3 promoter methylation for SLE (ROC)
- 0.769 [95% CI (0.681-0.814)] · diagnostic power (ROC)
- RUNX3 promoter methylation, SLE with vs without renal involvement (subgroup): SLE with renal involvement 86.29 ± 10.30
- RUNX3 promoter methylation, SLE with vs without renal involvement (subgroup): SLE without renal involvement 40.28 ± 24.21
Correlation of RUNX3 methylation with creatinine and C4
- Positive correlation between RUNX3 methylation level and levels of creatinine and C4
Original publication
Significant heightened methylation levels of RUNX3 gene promoter in patients with systemic lupus erythematosus. Lupus. Published 21 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →